The overall aim of the studies described in this application is to relate alterations in patterns of cytokine expression to the course of HIV infection and disease, by quantifying cytokine production in specific subpopulations of men in the Multicenter AIDS Cohort Study (MACS). In preliminary studies, cytokines that control immune function were found to be altered substantially in HIV infection. The proposed studies are to determine: (1) whether high levels of those cytokines fostering cell-mediated immunity (the TH1 cytokines, interferon-gamma [IFN-gamma] and interleukin-2 [IL-2], as well as IL-12, a cytokine that induces TH1 cells) are associated with relatively stable CD4 T-cell levels and with the absence of opportunistic infection (OI) in HIV infection; (2) whether the predominance of TH2 cytokines (IL-4 and IL-10) is associated with falling CD4 T-cell levels and with the occurrence of OI in HIV infection; (3) whether increases in tumor necrosis factor alpha (TNF-alpha) and IL-6 gene expression/levels are associated with an adverse disease course in the HIV-infected, and whether these cytokines are a better predictor of disease progression than the over-expression of TH-2 cytokines (IL-4 and IL-10); and (4) whether individual and complex changes in cytokine expression have relevance for prognosis (relative hazard) and whether these changes provide prognostic information not available from the measurement of CD4 T-cell number or serum activation markers (e.g., neopterin or beta-2 microglobulin). The subpopulations for study include these cohorts from the MACS: (a) HIV seroconverters; (b) HIV-seropositive men with different rates of decline of CD4 T-cell numbers; (c) HIV-positive men progressing to the acquired immunodeficiency syndrome (AIDS) within three years; (d) long-term HIV-positive survivors with little or no measurable loss of CD4 T-cells; (e) HIV-positive men who have had low CD4 numbers for an extended period of time without the occurrence of OI; and (f) a sample in which selected cytokines can be evaluated for relative hazard of AIDS occurrence. The researchers will measure: (1) serum levels of these cytokines; (2) levels of cytokine gene expression (mRNA) in peripheral blood mononuclear cells (PBMC's) by RNA polymerase chain reaction (PCR); and (3) cytokine production and levels of cytokine mRNA in response to in vitro stimulation of PBMC in the HIV-positive men and in HIV-negative men.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI036086-02
Application #
2072160
Study Section
AIDS and Related Research Study Section 2 (ARRB)
Project Start
1994-07-01
Project End
1998-01-31
Budget Start
1995-02-01
Budget End
1996-01-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Mildvan, Donna; Spritzler, John; Grossberg, Sidney E et al. (2005) Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis 40:853-8
Breen, E C; McDonald, M; Fan, J et al. (2000) Cytokine gene expression occurs more rapidly in stimulated peripheral blood mononuclear cells from human immunodeficiency virus-infected persons. Clin Diagn Lab Immunol 7:769-73
Aziz, N; Nishanian, P; Mitsuyasu, R et al. (1999) Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol 6:89-95
Plaeger, S; Bass, H Z; Nishanian, P et al. (1999) The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes. Clin Immunol 90:238-46
van der Meijden, M; Gage, J; Breen, E C et al. (1998) IL-6 receptor (CD126'IL-6R') expression is increased on monocytes and B lymphocytes in HIV infection. Cell Immunol 190:156-66
Nishanian, P; Aziz, N; Chung, J et al. (1998) Oral fluids as an alternative to serum for measurement of markers of immune activation. Clin Diagn Lab Immunol 5:507-12
Martinez-Maza, O; Widney, D; van der Meijden, M et al. (1998) Immune dysfunction and the pathogenesis of AIDS-associated non-Hodgkin's lymphoma. Mem Inst Oswaldo Cruz 93:373-81
Fahey, J L; Taylor, J M; Manna, B et al. (1998) Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS 12:1581-90
Nishanian, P; Taylor, J M; Manna, B et al. (1998) Accelerated changes (inflection points) in levels of serum immune activation markers and CD4+ and CD8+ T cells prior to AIDS onset. J Acquir Immune Defic Syndr Hum Retrovirol 18:162-70
Salazar-Gonzalez, J F; Martinez-Maza, O; Nishanian, P et al. (1998) Increased immune activation precedes the inflection point of CD4 T cells and the increased serum virus load in human immunodeficiency virus infection. J Infect Dis 178:423-30

Showing the most recent 10 out of 17 publications